retatrutide safety retatrutide clinical trial Availability & Timeline Triple hormone receptor agonist retatrutide

The treatment is highly customizable to your medical history, goals, and lab work

By understanding these connections and taking proactive steps to support hydration and electrolyte balance, you can harness the benefits of these diabetes and weight loss medications while maintaining the gut health thats so essential to your overall well-being

Reported side effects associated with MOTS-c in some contexts include increased heart rate, insomnia, and injection site irritation

Eli Lilly's retatrutide (LY3437943) was in Phase 3 trials as of 2025, with at least one stage expected to conclude in May 2026 [6]

A, D, and E can accumulate to harmful levels

Your Klinic provider will guide you on proper injection techniques and site rotation for optimal results